Cardiovascular Complications in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.

Allogeneic hematopoietic stem cell transplantation (HSCT) represents a major therapeutic strategy for malignant hematologic diseases, with the number of procedures steadily increasing in France each year. Conditioning and maintenance regimens carry a risk of both short- and long-term cardiotoxicity, leading to serious cardiovascular events including acute coronary syndrome (ACS), cardiac dysfunction, arrhythmias, pulmonary hypertension, and pericardial effusion. The pathophysiology of cardiotoxicity in HSCT patients remains poorly understood.

It is therefore crucial to investigate underlying mechanisms and identify predictive factors of cardiotoxicity in order to provide appropriate cardiological follow-up and management. Current European Society of Cardiology guidelines recommend routine monitoring of HSCT patients with echocardiography and cardiac biomarkers (NT-proBNP, troponin), although these recommendations are based on small-scale studies. The cardiodepressor factor DPP3 has shown promising results in cardio-oncology, with a causal role in anthracycline-induced cardiac dysfunction. Its role in HSCT-related cardiotoxicity requires further evaluation.

This multicenter study of HSCT recipients will be a valuable resource, enabling a better understanding of the pathophysiology of cardiotoxicity and prognosis. It will highlight imaging (echocardiography, calcium score, supra-aortic Doppler), electrocardiographic, and biological markers (including DPP3) associated with prognosis.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Cardiotoxicity ACS - Acute Coronary Syndrome Acute Coronary Syndrome Allogeneic Hematopoietic Stem Cell Transplantation Arrhythmias, Cardiac Arrythmia, Cardiac Cardiac Dysfunction Cardiovascular Diseases Chemically-Induced Disorders DPP3 Drug-Related Side Effects and Adverse Reactions HSCT Heart Diseases Hypertension Hypertension, Pulmonary Lung Diseases Machine Learning Myocardial Ischemia Pathologic Processes Pathological Conditions, Signs and Symptoms Pulmonary Hypertension Radiation Injuries Respiratory Tract Diseases Vascular Diseases Wounds and Injuries

Age range

15 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age ≥ 15 years
Informed about the study and without objection to participation (or with consent from legal guardians)
Undergoing allogeneic HSCT

Exclusion criteria

Patient not followed up at the participating center
Pregnant or breastfeeding women
Patient not affiliated with social security
Patient under guardianship, curatorship, or legal protection

Treatment and study plan

Primary outcomes

Composite cardiotoxicity outcome during follow-up of 1 year, defined as cardiovascular mortality, cardiac dysfunction, acute coronary syndrome, pericarditis, and supraventricular or ventricular arrhythmias.

Time frame: During follow-up of 1 year

Study contacts

Contact information is provided by the study sponsor or research team.

Trecy Dr Gonçalves, Dr

CONTACT

[email protected]

+33142499162

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Collaborators

Fédération Française de Cardiologie
INSERM U1086 Cancers et Préventions
INSERM UMR-S 942 MASCOT

Registry information

Acronym: ALLOCARDIOTOX

Important dates

Study start: 2025
Primary completion: 2027
Study completion: 2028
First posted: Sep 5, 2025
Registry last updated: Sep 5, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting